Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3145–3168 of 22,009 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
Interventions: Rifaximin SSD 40 mg IR tablet, Placebo; Drug
Lead sponsor: Jasmohan Bajaj; Federal
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Myasthenia Gravis
Interventions: Nipocalimab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more

Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions: L-NMMA; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Trauma and Stressor Related Disorders, Substance Use
Interventions: Finding Emotional Empowerment and Lifelong Strength; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 39
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more

Conditions: Stroke
Interventions: Ischemic Conditioning; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Scoliosis; Juvenile, Scoliosis; Adolescence
Interventions: Erector Spinae Plane Blockade; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Degenerative Disc Disease, Spinal Stenosis
Interventions: OssDsign® Catalyst; Device
Lead sponsor: OssDsign; Industry
Eligibility: 21 Years and older
Enrollment: 450 participants
Timeline: 2022 – 2030
U.S. locations: 16
States / cities: Fresno, California • Long Beach, California • San Diego, California + 13 more

Conditions: Pancreatic Cancer, Pancreatic Neoplasms, Diabetes Mellitus
Interventions: MRI/MRCP; Diagnostic Test
Lead sponsor: Nuvance Health; Other
Eligibility: 50 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Norwalk, Connecticut

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Durvalumab, Futibatinib, Magnetic Resonance Imaging, Radical Cystectomy; Procedure · Biological · Drug
Lead sponsor: Yuanquan Yang; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio

Conditions: Gaucher Disease, Type 3
Interventions: No intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Disease, Kidney Disease, Chronic, Kidney Disease, End-Stage, Kidney Diseases, Kidney Diseases, Chronic, Kidney Diseases,Cystic
Interventions: Saliva sample, Health surveys; Genetic · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more

Conditions: Alcohol Use Disorder (AUD), Healthy Controls Group - Age and Sex-matched
Interventions: [F-18]BCPP-EF, [F-18]FDG; Drug
Lead sponsor: Rajesh Narendran; Other
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more

Conditions: Ovarian Cancer
Interventions: Durvalumab, BA3011, BA3021, ENB003, Toripalimab; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Air cleaner, Sham air cleaner; Device
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 40 Years and older
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Iowa City, Iowa + 7 more

Conditions: Pregnancy, Overweight and Obesity
Interventions: Exercise Modes; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Deafness, Diabetes Insipidus, Ataxia
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 0 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Knee Osteoarthritis, Insomnia
Interventions: Personalized exercise coaching, Cognitive behavioral therapy for Insomnia; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: BK Polyomavirus
Interventions: BK-virus specific CTLs; Biological
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Weeks to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infertility, IVF
Interventions: Sperm Sorting; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: EXOMIND (BTL-699-2) Active treatment, EXOMIND (BTL-699-2) Sham treatment; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Newburgh, Indiana

Conditions: Cancer-related Venous Thromboembolism
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Rifaximin SSD in Dementia Trial

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Finding Emotional Empowerment and Lifelong Strength

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Blood Flow Regulation and Neuromuscular Function Post-Stroke

Erector Spinae Plane Blockade in Pediatric Scoliosis Surgery Patients

OssDsign® Spine Registry Study ("Propel")

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

Rutgers University Study of the Genetics of Kidney Disease

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Imaging Mitochondrial Complex-I in Alcohol Use Disorder

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Multi-Center Clean Air Randomized Controlled Trial in COPD

Pregnancy Exercise Mode Effect on Childhood Obesity

Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study

Move and Snooze: Adding Insomnia Treatment to an Exercise Program to Improve Pain Outcomes in Older Adults With Knee Osteoarthritis

Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

Sex Selection of Human Spermatozoa

Device for Treating Generalized Anxiety

Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization